E-ISSN: 2147-1959
Metachronous Brain Tumor in 177Lu-PSMA Scan in a Patient with Metastatic Castration Resistant Prostate Cancer Mimicking Disease Progression
PDF
Cite
Share
Request
Interesting Image
VOLUME: 32 ISSUE: 1
P: 54-56
February 2023

Metachronous Brain Tumor in 177Lu-PSMA Scan in a Patient with Metastatic Castration Resistant Prostate Cancer Mimicking Disease Progression

Mol Imaging Radionucl Ther 2023;32(1):54-56
DOI: 10.4274/mirt.galenos.2021.55376
Elahe Pirayesh
Mehrdad Tavakoli
1. Shahid Beheshti University of Medical Sciences School of Medicine, Shohadae Tajrish Medical Center, Department of Nuclear Medicine, Tehran, Iran
No information available.
No information available
Received Date: 28.06.2020
Accepted Date: 05.01.2021
Publish Date: 23.02.2023
PDF
Cite
Share
Request

ABSTRACT

A 66-year old man known case of metastatic castration resistant prostate cancer underwent successful 6 cycles treatment with 177Lu- prostate-specific membrane antigen. On the last post therapy whole body scan a new lesion in the skull was noted, suspected for disease progression. One week later, the patient complained from weakness of left upper extremity and brain magnetic resonance imaging revealed a brain tumor, confirmed as glioblastoma pathologically.

References

1
Norouzi G, Aghdam RA, Hashemifard H, Pirayesh E. Excellent response to lower dose of 177Lu-PSMA-617 in a metastatic castration-resistant prostate cancer patient with a transplanted kidney. Clin Nucl Med 2019;44:483-484.
2
Vogt A, Schmid S, Heinimann K, Frick H, Herrmann C, Cerny T, Omlin A. Multiple primary tumours: challenges and approaches, a review. ESMO Open 2017;2:e000172.
3
Hamza MA, Kamiya-Matsuoka C, Liu D, Yuan Y, Puduvalli VK. Outcome of patients with malignant glioma and synchronous or metachronous non-central nervous system primary neoplasms. J Neurooncol 2016;126:527-533.
4
Osman MM, Iravani A, Hicks RJ, Hofman MS. Detection of synchronous primary malignancies with 68Ga-labeled prostate-specific membrane antigen PET/CT in patients with prostate cancer: frequency in 764 patients. J Nucl Med 2017;58:1938-1942.
5
Grace S, Muzaffar R, Veerapong J, Alkaade S, Poddar N, Phillips N, Guzman M, Batanian J, Vogler C, Lai JP. Synchronous quadruple primary neoplasms: glioblastoma, neuroendocrine tumor, schwannoma and sessile serrated adenoma in a patient with history of prostate cancer. Anticancer Res 2015;35:2121-2127.
6
Neri D, Bicknell R. Tumour vascular targeting. Nat Rev Cancer 2005;5:436-446.
7
Salas Fragomeni RA, Amir T, Sheikhbahaei S, Harvey SC, Javadi MS, Solnes LB, Kiess AP, Allaf ME, Pomper MG, Gorin MA, Rowe SP. Imaging of nonprostate cancers using PSMA-targeted radiotracers: rationale, current state of the field, and a call to arms. J Nucl Med 2018;59:871-877.